The present invention relates to giant nucleons designed to recognize and isolate a recognition sequence within an open reading framework of at least two hepatitis B virus (VHB) genes. Current inventions also include the use of this design-type super-large Nucleon in pharmaceutical ingredients, as well as treatment or reduction of symptoms of VHB infection or treatment of liver cancer (CHC). In addition, the invention also includes pharmaceutical ingredients consisting of genetically engineered giant nuclear proteins.Encoding the designed giant nucleic acids and using these compounds to treat nucleic acids infected with VHB or CHCTHE, submitting the invention of shrinkage works, large nuclei, and recognizing and clarifying their consequences in an open reading framework (or)(RF) of the genome of at least two genotypes of the hepatitis B virus (HBV). The present invention and encompasses methods of using such engineered Maga ribose in a pharmaceutical composition and in methods for treating or reducing the symptoms of a HBV infectionOr treat hepatocellular carcinoma (HCC). Further, the invention encompasses pharmaceutical compositions include engineered meganuclease proteins, nucleic acids encoming engineered meganucleases, and the use of such compositions for treating HBV infections or HCC.La presente invención abarca meganucleasas de diseño que reconocen y escinden una secuencia de reconocimiento dentro de un marco de lectura abierto (ORF) del genoma de al menos dos genotipos del virus de la hepatitis B (VHB). La presente invención también abarca métodos para usar tales meganucleasas de diseño en una composición farmacéutica y en métodos para tratar o reducir los síntomas de una infección por VHB, o para tratar el carcinoma hepatocelular (CHC). Además, la invención abarca composiciones farmacéuticas que comprenden proteínas de meganucleasas modificadas por ingeniería genética, ácidos nucleicos que codifican meganucleasas de diseño y el uso de tales composiciones pa
